FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to biotechnology and can be used in producing insulin preparations for therapeutic applications. What is presented is a complex of a conjugate of insulin with a bivalent cation of a group II metal or a transient metal, wherein insulin is conjugated with a modifying group: -X-R1-Y-PAG-Z-R2 (IV), wherein: X, Y and Z represents independently the chosen binding groups and each of them optionally presents, and X, if presents, is bound to the compound insulin by a covalent bond, wherein X, Y, Z can be independently specified in -S-, -O-, -NH- and -C(O)-; at least one of R1 or R2 presents and represents lower alkyl optionally containing a carbonyl group, and provide R1 represents lower alkyl, then R2 represents a blocking group specified in -CH3, -H, tosylate or -C(O)OH; PAG represents a linear or branched carbon chain containing one or more PEG groups containing 2 to 10 of (CH2CH2O)-subunits, and optionally containing one or more additional groups specified in-S-, -O-, -NH- and -C(O)-; and wherein the modifying group has the maximum number of 3 to 25 heavy atoms specified in C, S, N and O, and bound to lysine in a position specified in a group consisting of the positions B26, B27, B28, B29 and B30 insulin within 5 amino acids of C-terminal of B-chain, thereby producing a monoconjugate. The conjugate of insulin is the same or more soluble than the respective non-conjugated insulin, and water solubility of the conjugate of insulin is reduced by adding zinc. The inventions also involve a method for preparing these complexes, pharmaceutical compositions for treating insulin deficiency in a human, containing these complexes and using them in preparing a drug for treating diabetes.
EFFECT: prepared complexes show improved chemical stability as compared to the conjugates of insulin not in the complex.
51 cl, 42 dwg, 40 tbl, 86 ex
Title | Year | Author | Number |
---|---|---|---|
INSULIN-OLIGOMER CONJUGATES, PREPARATIONS AND USE THEREOF | 2005 |
|
RU2393168C2 |
IMPROVED CHELATE CONJUGATES | 2002 |
|
RU2298012C2 |
SOLID PHARMACEUTICAL COMPOSITION (VERSIONS) AND METHOD FOR CONTROLLING GLUCOSE CONCENTRATION THEREWITH, METHOD FOR PREPARING SOLID PHARMACEUTICAL COMPOSITIONS (VERSIONS), TABLET (VERSIONS) AND METHOD FOR MAKING AMORPHOUS PARTICLES | 2008 |
|
RU2453332C2 |
IMPROVED CONJUGATES N4 OF CHELATING AGENTS | 2005 |
|
RU2360701C2 |
LONG-ACTING INSULIN COMPOSITION | 2010 |
|
RU2556340C2 |
PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
OXADIAZOLONE DERIVATIVES AS PPAR-DELTA AGONISTS | 2005 |
|
RU2374243C2 |
PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | 2013 |
|
RU2719579C2 |
PRODRUG CONTAINING A SELF-CLEAVABLE LINKER | 2018 |
|
RU2798085C2 |
Authors
Dates
2014-09-10—Published
2005-07-19—Filed